Clinical trials: Eczema/Atopic Dermatitis
Atopic Dermatitis
SAR231893-LPS15497- "Dupilumab Effect on Sleep in AD Patients"
Primary Objective: To evaluate the effect of dupilumab on sleep quality in adult participants with moderate to severe atopic dermatitis (AD).
- Trial name
- NCT04033367
- Testing
- Dupilumab
- Where
- 42 sites in United States, Australia and 8 more
- Volunteers
- 188 people
- Sponsor
- Sanofi
Atopic Dermatitis
Effects of Tralokinumab in the Skin: an Immunologic and Molecular Investigation
The clinical efficacy of tralokinumab has been demonstrated in the treatment of AD; its MOA however remains insufficiently understood.
- Trial name
- TRALIS (NCT05378698)
- Testing
- Application of Tralokinumab
- Where
- Switzerland
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Zurich
Atopic Dermatitis
AD Treatment Optimization With Ebglyss in Real-World Practice: A Multicenter Study of Patient-Centered Outcomes
The goal of this Phase 4 clinical study is to learn how Ebglyss (lebrikizumab) works and how it is dosed in everyday dermatology care for adults and adolescents (age 12 and older) with moderate-to-severe atopic dermatitis…
- Trial name
- AD-TEMPO (NCT07856134)
- Testing
- Lebrikizumab-lbkz
- Where
- 10 sites in United States
- Volunteers
- 250 people
- Sponsor
- Forefront Dermatology S.C
Atopic Dermatitis, Food Allergies
Probiotic Supplementation in Breastfed Newborn Infants
The purpose of this study is to investigate the dose of a probiotic supplement (Bifidobacterium longum subsp. infantis) required to achieve predominant gut colonization in healthy newborn, breastfed infants.
- Trial name
- NCT02286999
- Testing
- B. infantis
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Emanual Maverakis, MD
Atopic Dermatitis
A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Moderate to Severe Atopic Dermatitis
This study will assess the efficacy and safety of MSTT1041A (astegolimab) in participants with moderate to severe atopic dermatitis (AD).
- Trial name
- NCT03747575
- Testing
- MSTT1041A
- Where
- 21 sites in United States, Germany and 1 more
- Volunteers
- 65 people
- Sponsor
- Genentech, Inc.
Atopic Dermatitis
Phase 2 Study of KHK4577
This study is an randomized double-blind placebo-controlled study to evaluate the efficacy and the safety of oral KHK4577 for 6 weeks in patients with atopic dermatitis. Pharmacokinetics of KHK4577 will also be assessed.
- Trial name
- NCT02004119
- Testing
- KHK4577
- Where
- Japan
- Volunteers
- 93 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Healthy
A Study of a Probiotic Food Supplement Containing B. Infantis (EVC001) in Healthy Breastfed Infants at Risk of Developing Atopic Dermatitis
The purpose of this study is to assess the effect of B. infantis (EVC001) versus placebo supplementation, in healthy breastfed infants at risk of developing atopic dermatitis (AD), on cumulative incidence of physician-diagnosed…
- Trial name
- NCT04662619
- Testing
- B. infantis
- Where
- Finland
- Volunteers
- 273 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Consumer Inc. (J&JCI)
Chronic Pruritus, Eczema
Efficacy of Topical Cannabidiol for Eczema
Itching is a common symptom encountered in general medical practice. It can cause significant discomfort, disrupt sleep, and impair patients' quality of life.
- Conditions
- Chronic Pruritus, Eczema, Nummular Eczema, Atopic Dermatitis
- Trial name
- NCT06994520
- Testing
- Cannabidiol (CBD), Triamcinolone (TAC) 0.1% cream
- Where
- Thailand
- Volunteers
- 60 people
- Sponsor
- Khon Kaen University
Overall Skin Appearance, Dry Skin; Eczema
RCT to Evaluate the Cosmetic Efficacy of Demo-cosmetic Active Ingredient CLS02021
This study will explore the potential of probiotic based, novel cosmetic active ingredient to rebuild the collagen based skin barrier with the overall aim to rejuvenate ageing or damaged skin, improve skin integrity, appearance…
- Trial name
- NCT05048121
- Testing
- Cosmetic Active Ingredient CLS02021
- Where
- 2 sites in Bosnia and Herzegovina
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Anbiome Labs LLC
Normal Volunteers, Atopic Dermatitis (AD)
Safety, Tolerability and PK of ATTO-3712 in Healthy Volunteers and Patients With Atopic Dermatitis
The goal of this clinical trial is to assess the safety, tolerability, and pharmacokinetics of ATTO-3712 in healthy adults and patients with atopic dermatitis.
- Conditions
- Normal Volunteers, Atopic Dermatitis (AD), Atopic Eczema, Atopic Eczema/Dermatitis (Non-Specific)
- Trial name
- NCT07205081
- Testing
- ATTO-3712
- Where
- 17 sites in United States, Canada and 1 more
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Attovia Therapeutics Inc
Dermatitis, Atopic
Multiple Rising Dose Study of MK-6194 in Participants With Atopic Dermatitis (MK-6194-008)
The primary objective of this study is to characterize the safety and tolerability of MK-6194 following multiple doses among participants with moderate to severe atopic dermatitis who are unresponsive to other therapies.
- Trial name
- NCT05450198
- Testing
- MK-6194
- Where
- 19 sites in United States, Belgium and 4 more
- Volunteers
- 72 people
- Sponsor
- Merck Sharp & Dohme LLC
Atopic Dermatitis
Efficacy Study of Montelukast in Atopic Dermatitis Induced by Food Allergens
AD is a disease found in children; the focus of the study is the mechanisms associated in children with AD induced by food allergies.
- Trial name
- NCT00557284
- Testing
- Montelukast
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- 1st Allergy & Clinical Research Center
Atopic Dermatitis
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Topical therapies applied over the skin may not be enough to control the AD in trial participants who require systemic…
- Trial name
- Start Up (NCT06461897)
- Testing
- Upadacitinib, Dupilumab
- Where
- 150 sites in United States, Argentina and 24 more
- Volunteers
- 699 people
- Sponsor
- AbbVie
Atopic Dermatitis
An Observational Study to Assess Real-World Use of Upadacitinib Tablets in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis in China
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Upadacitinib is an approved drug for treating AD.
- Trial name
- REACH-AD (NCT06421740)
- Where
- 38 sites in China
- Volunteers
- 1,000 people
- Sponsor
- AbbVie
Atopic Dermatitis
The Role of Filaggrin and FADS Genes on the Concentrations of PUFA Towards Its Effect on Atopic Dermatitis in Infants
The incidence of atopic dermatitis has increased dramatically in this years. Atopic dermatitis occurs due to complex interactions between genetic and environmental factors.
- Trial name
- FLG-FADSgen (NCT02401178)
- Where
- Indonesia
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Universitas Indonesia
Atopic Dermatitis, Atopic Dermatitis Eczema
Characterizing Skin Microbiome Change in Atopic Dermatitis
Atopic dermatitis (AD), also known as eczema, is an inflammatory disease of the skin affecting a large proportion of the pediatric and adult patient population.
- Trial name
- NCT04800185
- Testing
- Crisaborole 2% Top Oint, Skin Microbiome Swabs
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of California, Irvine
Eczema, Atopic Dermatitis
Management of Eczema by Specific Probiotic Strains
To investigate the therapeutic effect of a selected probiotic mixture on the severity of AD in infants aged 0-15 months. The probiotic mixture has been studied in laboratory setting and has proven IL-10 stimulating effects.
- Trial name
- BAMBOO (NCT01230190)
- Testing
- Ecologic ® Panda II
- Where
- Netherlands
- Volunteers
- healthy volunteers welcome
- Sponsor
- Agentschap NL
Atopic Dermatitis
Correlation Study Between PEST and SCORAD in Management of Atopic Dermatitis With Ceradan® Regimen
This is a prospective, open label, single arm, and observational and multicenter study to assess the correlation between PEST and SCORAD scores in the management of AD with the Ceradan® regimen.
- Trial name
- COPES (NCT02073591)
- Testing
- Ceradan Cream, Ceradan Wash
- Where
- 2 sites in Singapore
- Volunteers
- 58 people
- Sponsor
- Hyphens Pharma Pte Ltd
Atopic Dermatitis, Eczema
Monitoring Pregnancy and Infant Outcomes Following Tralokinumab Exposure During Pregnancy in the US and Canada - PROTECT
The goal of this observational study is to learn about exposure to tralokinumab during pregnancy, as well as atopic dermatitis (AD) during pregnancy.
- Trial name
- PROTECT (NCT05938478)
- Testing
- Tralokinumab
- Where
- United States
- Volunteers
- 900 people
- Sponsor
- University of California, San Diego
Atopic Dermatitis (AD)
Effect of an Emollient Cream Containing a Milk Bioactive Peptide on Clinical Signs, Pruritus and Bacterial Colonization of Mild Atopic Dermatitis Skin Lesions in Pediatric Population
The goal of this clinical trial is to evaluate the protective effect of glycomacropeptide on the clinical signs and symptoms of atopic dermatitis in children aged 2 to 12 years, and to determine if topical administration of…
- Trial name
- AD-GMP-SCORAD (NCT07259343)
- Testing
- glycomacropeptide, emollient cream
- Where
- Mexico
- Volunteers
- 20 people
- Sponsor
- Universidad Autónoma de Aguascalientes
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.